Cargando…

Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B

For long-term treatment of hepatitis B virus (HBV) infection, switching from tenofovir-disoproxil-fumarate (TDF) to tenofovir-alafenamide (TAF) may prevent renal dysfunction and bone loss. However, the precise effects of this switch on the blood lipid profile remain to be clarified. This is an impor...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Kazuharu, Suda, Goki, Yamamoto, Yoshiya, Abiko, Satoshi, Kinoshita, Kenji, Miyamoto, Shuichi, Sugiura, Ryo, Kimura, Megumi, Maehara, Osamu, Yamada, Ren, Kitagataya, Takashi, Shigesawa, Taku, Ohara, Masatsugu, Kawagishi, Naoki, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Ogawa, Koji, Sakamoto, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775237/
https://www.ncbi.nlm.nih.gov/pubmed/35051189
http://dx.doi.org/10.1371/journal.pone.0261760
_version_ 1784636537175015424
author Suzuki, Kazuharu
Suda, Goki
Yamamoto, Yoshiya
Abiko, Satoshi
Kinoshita, Kenji
Miyamoto, Shuichi
Sugiura, Ryo
Kimura, Megumi
Maehara, Osamu
Yamada, Ren
Kitagataya, Takashi
Shigesawa, Taku
Ohara, Masatsugu
Kawagishi, Naoki
Nakai, Masato
Sho, Takuya
Natsuizaka, Mitsuteru
Morikawa, Kenichi
Ogawa, Koji
Sakamoto, Naoya
author_facet Suzuki, Kazuharu
Suda, Goki
Yamamoto, Yoshiya
Abiko, Satoshi
Kinoshita, Kenji
Miyamoto, Shuichi
Sugiura, Ryo
Kimura, Megumi
Maehara, Osamu
Yamada, Ren
Kitagataya, Takashi
Shigesawa, Taku
Ohara, Masatsugu
Kawagishi, Naoki
Nakai, Masato
Sho, Takuya
Natsuizaka, Mitsuteru
Morikawa, Kenichi
Ogawa, Koji
Sakamoto, Naoya
author_sort Suzuki, Kazuharu
collection PubMed
description For long-term treatment of hepatitis B virus (HBV) infection, switching from tenofovir-disoproxil-fumarate (TDF) to tenofovir-alafenamide (TAF) may prevent renal dysfunction and bone loss. However, the precise effects of this switch on the blood lipid profile remain to be clarified. This is an important issue as TDF is known to have effects on both low- and high-density lipids. Therefore, our retrospective multi-center study aimed to evaluate the effects of switching from TDF to TAF on the lipid profile of patients with HBV infection. Samples were obtained prior to the switch from TDF to TAF and at 6–12 months after TAF initiation. In some cases, additional samples obtained pre- and post-TDF administration were available for analysis. Serum cholesterol levels, including oxidized-low-density lipoprotein (LDL) and non-high-density lipoprotein-cholesterol (HDL-c), and the rate of dyslipidemia, according to the NCEP-ATP III lipid risk classification, were analyzed. The data from 69 patients were analyzed, including 33 patients with pre- and post-TDF-initiation serum samples. Total cholesterol (T-chol), HDL-c, LDL-c, non-HDL-c, and oxidized LDL levels increased significantly after switching to TAF. With regard to sequential changes pre- to post-TAF, TDF was associated with significantly lower serum T-chol, HDL-c, and oxidized LDL-c levels, with T-chol, HDL-c, LDL-c, and oxidized LDL-c levels increasing significantly after the switch. The switch from TDF to TAF was also associated with an increase in the rate of dyslipidemia, from 33% to 39%, with an increase in the rate of severe dyslipidemia of 1.4% and 5.8%, based on T-chol and LDL-c levels. Of note, no cases of severe dyslipidemia were detected pre-TAF treatment. As oxidized LDL-c and non-HDL-c are strongly associated with atherosclerosis development, careful monitoring of lipid is needed after switching from TDF to TAF in this clinical population.
format Online
Article
Text
id pubmed-8775237
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-87752372022-01-21 Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B Suzuki, Kazuharu Suda, Goki Yamamoto, Yoshiya Abiko, Satoshi Kinoshita, Kenji Miyamoto, Shuichi Sugiura, Ryo Kimura, Megumi Maehara, Osamu Yamada, Ren Kitagataya, Takashi Shigesawa, Taku Ohara, Masatsugu Kawagishi, Naoki Nakai, Masato Sho, Takuya Natsuizaka, Mitsuteru Morikawa, Kenichi Ogawa, Koji Sakamoto, Naoya PLoS One Research Article For long-term treatment of hepatitis B virus (HBV) infection, switching from tenofovir-disoproxil-fumarate (TDF) to tenofovir-alafenamide (TAF) may prevent renal dysfunction and bone loss. However, the precise effects of this switch on the blood lipid profile remain to be clarified. This is an important issue as TDF is known to have effects on both low- and high-density lipids. Therefore, our retrospective multi-center study aimed to evaluate the effects of switching from TDF to TAF on the lipid profile of patients with HBV infection. Samples were obtained prior to the switch from TDF to TAF and at 6–12 months after TAF initiation. In some cases, additional samples obtained pre- and post-TDF administration were available for analysis. Serum cholesterol levels, including oxidized-low-density lipoprotein (LDL) and non-high-density lipoprotein-cholesterol (HDL-c), and the rate of dyslipidemia, according to the NCEP-ATP III lipid risk classification, were analyzed. The data from 69 patients were analyzed, including 33 patients with pre- and post-TDF-initiation serum samples. Total cholesterol (T-chol), HDL-c, LDL-c, non-HDL-c, and oxidized LDL levels increased significantly after switching to TAF. With regard to sequential changes pre- to post-TAF, TDF was associated with significantly lower serum T-chol, HDL-c, and oxidized LDL-c levels, with T-chol, HDL-c, LDL-c, and oxidized LDL-c levels increasing significantly after the switch. The switch from TDF to TAF was also associated with an increase in the rate of dyslipidemia, from 33% to 39%, with an increase in the rate of severe dyslipidemia of 1.4% and 5.8%, based on T-chol and LDL-c levels. Of note, no cases of severe dyslipidemia were detected pre-TAF treatment. As oxidized LDL-c and non-HDL-c are strongly associated with atherosclerosis development, careful monitoring of lipid is needed after switching from TDF to TAF in this clinical population. Public Library of Science 2022-01-20 /pmc/articles/PMC8775237/ /pubmed/35051189 http://dx.doi.org/10.1371/journal.pone.0261760 Text en © 2022 Suzuki et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Suzuki, Kazuharu
Suda, Goki
Yamamoto, Yoshiya
Abiko, Satoshi
Kinoshita, Kenji
Miyamoto, Shuichi
Sugiura, Ryo
Kimura, Megumi
Maehara, Osamu
Yamada, Ren
Kitagataya, Takashi
Shigesawa, Taku
Ohara, Masatsugu
Kawagishi, Naoki
Nakai, Masato
Sho, Takuya
Natsuizaka, Mitsuteru
Morikawa, Kenichi
Ogawa, Koji
Sakamoto, Naoya
Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B
title Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B
title_full Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B
title_fullStr Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B
title_full_unstemmed Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B
title_short Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B
title_sort effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis b
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8775237/
https://www.ncbi.nlm.nih.gov/pubmed/35051189
http://dx.doi.org/10.1371/journal.pone.0261760
work_keys_str_mv AT suzukikazuharu effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb
AT sudagoki effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb
AT yamamotoyoshiya effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb
AT abikosatoshi effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb
AT kinoshitakenji effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb
AT miyamotoshuichi effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb
AT sugiuraryo effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb
AT kimuramegumi effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb
AT maeharaosamu effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb
AT yamadaren effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb
AT kitagatayatakashi effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb
AT shigesawataku effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb
AT oharamasatsugu effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb
AT kawagishinaoki effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb
AT nakaimasato effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb
AT shotakuya effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb
AT natsuizakamitsuteru effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb
AT morikawakenichi effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb
AT ogawakoji effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb
AT sakamotonaoya effectofswitchingfromtenofovirdisoproxilfumaratetotenofoviralafenamideonlipidprofilesinpatientswithhepatitisb